Evaxion Biotech A/S (Nasdaq: EVAX), a pioneering clinical-stage TechBio company, has announced promising results from its Phase II clinical trial for the personalized cancer vaccine candidate, EVX-01. The latest data reveal a substantial 69% overall response rate (ORR), with 11 out of 16 patients achieving objective clinical responses. Furthermore, 15 of the 16 patients showed tumor reduction, underscoring the vaccine’s potential efficacy in treating advanced melanoma.
Key Findings from the Phase II Trial
The Phase II trial, which is evaluating EVX-01 in combination with Merck & Co.’s Keytruda (pembrolizumab), is part of an ongoing study focused on patients with advanced melanoma. The interim analysis covering one year of treatment has provided a positive outlook on EVX-01’s effectiveness. The combination therapy aims to leverage the strengths of both the personalized vaccine and the established immune checkpoint inhibitor.
EVX-01, designed using Evaxion’s proprietary AI-Immunology™ platform, is a personalized peptide-based vaccine that targets specific tumor antigens unique to each patient. This personalized approach is intended to enhance the immune system’s ability to recognize and attack cancer cells more effectively. The trial results indicate that the vaccine not only promotes robust immune responses but also complements the effects of Keytruda, a leading PD-1 inhibitor used in cancer immunotherapy.
Presentation at ESMO Congress 2024
The complete dataset from this Phase II trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in Barcelona, Spain, from September 13-17, 2024. The presentation, scheduled for September 14, will be delivered by Dr. Paola Queirolo, Director of Medical Oncology of Melanoma, Sarcoma, and Rare Tumors at the European Institute of Oncology in Milan. The session will include a detailed examination of the trial results and their implications for future treatment strategies.
Webinar Discussion on September 18
In addition to the ESMO presentation, Evaxion Biotech will host a webinar on September 18, 2024, featuring Professor Georgina V. Long, a leading expert and principal investigator for the study. The webinar will provide further insights into the trial’s findings and discuss the broader impact of EVX-01 on melanoma treatment. Participants will have the opportunity to engage in a Q&A session, addressing specific questions and concerns about the vaccine and its potential applications.
Innovative Approach with AI-Immunology™
EVX-01 represents a significant advancement in the field of cancer immunotherapy, driven by Evaxion’s AI-Immunology™ platform. This innovative technology uses artificial intelligence to analyze and predict the most effective vaccine targets based on an individual’s unique tumor profile and immune system characteristics. The platform’s ability to tailor treatments to each patient’s specific needs offers a promising avenue for improving cancer care and outcomes.
Future Directions
Evaxion Biotech is optimistic about the continued development of EVX-01 and its potential to transform melanoma treatment. The company is committed to advancing the Phase II trial and exploring additional opportunities for collaboration and partnership. With the support of cutting-edge technology and a focus on personalized medicine, Evaxion aims to address the significant unmet needs in cancer treatment and provide new hope for patients battling advanced melanoma.
